Jubilant Pharmova's US Subsidiary Aces USFDA Pharmacovigilance Inspection

Jubilant Pharmova Limited's subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA, successfully completed a USFDA Post-marketing Adverse Drug Experience (PADE) inspection on September 19, 2025, with no observations. This outcome reaffirms the company's commitment to maintaining high quality and safety standards in the pharmaceutical industry. Jubilant Pharmova, a global pharmaceutical company, operates in various segments including Radiopharma, Allergy Immunotherapy, CDMO, CRDMO, and Generics and Proprietary Novel Drugs.